 
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617340]  
Mississauga, Ontario, L4W 1N2  
Canada  
 
17-May-2010 
Final Version 1.0 
 
                                
 
 
Written By:     
 [CONTACT_480349], M.Sc.  
Manager Biostatistics  
Cetero Research  
 
 
  Date  
Approved by:     
 [CONTACT_25715][INVESTIGATOR_28947] D'Angelo, M.Sc.  
Director Biostatistics  & PK/PD  
Cetero Research  
 
 
 
  Date  
    
 
 Yuan -Di  Halvorsen, Ph.D.  
Clinical  Project  Leader   
Theracos , Inc.  
 
  Date  
 
 
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617341] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AE adverse event  
ANOVA  analysis of variance  
ATC the anatomic therapeutic chemical classification  
AUC  area under the curve  
AUC 0-t area under the plasma concentration -time curve from time 0 to time t 
(time of last quantifiable plasma concentration)  
AUC 0-inf area under the plasma concentration -time curve from time 0 to infinity  
AUC 0-24 area under the plasma concentration -time curve from time 0 to 24 h  
BMI body mass index  
CI confidence interval  
CL/F  the a pparent total body  clearance  
Cmax maximum observed plasma concentration  
CRF case report form  
CV coefficient of variation  
DSMB  data and safety monitoring board  
ECG  electrocardiogram  
FDA food and drug administration  
FPG fasting plasma glucose  
GCP  good clinical practice  
HbA1c  glycated hemoglobin  
ICH international conference on harmonisation  
ITT intent -to-treat 
Kel terminal phase rate constant   
MedDRA  medical dictionary for regulatory activities  
PK pharmacokinetics  
PP per protocol  
SAE serious adverse event  
SAP statistical analysis  plan 
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617342] dose  
Vz/F the a pparent total volume of distribution  
 
 
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617343] of Abbreviations and Definitions of Terms  ................................ ................................ ........  2 
1. INTRODUCTION  ................................ ................................ ................................ ................  8 
2. OBJECTIVES  ................................ ................................ ................................ .....................  8 
3. OVERALL STUDY  DESIGN AND PLAN  ................................ ................................ ............  9 
4. TREATMENT ADMINISTERED  ................................ ................................ ........................  10 
5. BLINDING  ................................ ................................ ................................ ........................  10 
6. METHOD OF ASS IGNING SUBJECTS TO TREATMENT GROUPS  ...............................  11 
7. SAMPLE SIZE  ................................ ................................ ................................ ..................  11 
8. ANALYSIS POPULATIONS  ................................ ................................ .............................  12 
9. STUDY ENDPOINTS  ................................ ................................ ................................ ....... 13 
10. STATISTICAL METHODS  ................................ ................................ ..............................  13 
10.1 Baseline Characteristics  ................................ ................................ ...............................  14 
10.1.1 Demographics and Baseline Characteristics ................................ ..............................  14 
10.1.2 Medical History  ................................ ................................ ................................ ..........  14 
10.1.3 Inclusion/Exclusion Criteria and Exceptions ................................ ...............................  [ADDRESS_617344] -prandial Blood Glucose  ................................ .............  19 
10.7 Interim Analysis  ................................ ................................ ................................ ............  19 
10.8 M issing Data  ................................ ................................ ................................ ................  20 
10.9 Multiple Comparisons  ................................ ................................ ................................ ... 20 
11. TABLE, LISTING AND FIGURE SHELLS  ................................ ................................ ....... 20 
 
Tables:  
 
Table 14.1.1 Disposition of Subjects (Double -blind Segment)  ................................ ..............  22 
Table 14.1.2 Disposition of Subjects  (Dose Escalation Segment)  ................................ .........  23 
Table 14.1.3 Summary of Demographics (Double -blind Segment)  ................................ ....... 24 
Table 14.1.4 Summary of Demographics (Dose Escalation Segment)  ................................ . 26 
Table 14.2.1 Primary Efficacy Analysis: Descriptive Summary of Fasting Plasma Glucose 
from Baseline to End of Treatment Double -blind Segment Intent -to-Treat Analysis Set  28 
Table 14.2.2 Primary Efficacy Analysis: ANCOVA Results on Mean Change in FPG from 
Baseline to End of Treatment Double -blind Segment Intent -to-Treat Analysis Set  ........  [ADDRESS_617345] 
Treatment Double -blind Segment Inten t-to-Treat Analysis Set  ................................ ..... 32 
Table 14.2.7 Descriptive Summary of Change in Body Weight from Baseline to Day 29 
Double -blind Segment   Intent -to-Treat Analysis Set ................................ ......................  33 
Table 14.2.8 ANCOVA Results on Mean Change in Body Weight from Baseline to Day 29  
Double -blind Segment Intent -to-Treat Analysis Set ................................ .......................  34 
Table 14.2.9 Descriptive Summary of Change in HbA1c from Baseline to Day 29  Double -
blind Segment  Intent -to-Treat Analysis Set  ................................ ................................ .. 35 
Table 14.2.10 ANCOVA Results on Mean Change in HbA1c from Baseline to Day 29 
Double -blind Segment Intent -to-Treat Analysis Set ................................ .......................  36 
Table 14.2.11 Descriptive Summary of Change in 24 h UGE from Baseline to Day 28 
Double -blind Segment  Intent -to-Treat Analysis Set ................................ ......................  37 
Table 14.2.12 ANCOVA Results on Mean Change in 24 h UGE from Baseline to Day 28  
Double-blind Segment Intent -to-Treat Analysis Set ................................ .......................  38 
Table 14.2.13 Summary of Plasma Concentrations of EGT0001442 (ng/mL)   Dose 
Escalation Segment  ................................ ................................ ................................ ...... [ADDRESS_617346] Prandial Blood Glucose (mg/dL) in Change from Day [ADDRESS_617347] Prandial Blood Glucose in AUC  Dose Escalation 
Segment  ................................ ................................ ................................ .......................  42 
Table [IP_ADDRESS] Summary of TEAEs  Double -blind Segment  Double -blind Safety Analysis 
Set ................................ ................................ ................................ ................................  43 
Table [IP_ADDRESS] Summary of TEAEs  Dose Escalation Segment  Dose Escalation Safety 
Analysis Set  ................................ ................................ ................................ ..................  44 
Table [IP_ADDRESS] Summary of TEAEs by [CONTACT_1196], Preferred Term and 
Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  ................  45 
Table [IP_ADDRESS] Summary of Drug -related TEAEs by [CONTACT_1196], Preferred Term 
and Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  .........  46 
Table [IP_ADDRESS] Summary of TEAEs Leading to Study Discontinuation by [CONTACT_12360], Preferred Term and Treatment Group Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 46 
Table [IP_ADDRESS] Summary of Serious TEAEs by [CONTACT_1196], Preferred Term and 
Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  ................  46 
Table [IP_ADDRESS] Summary of TEAEs by [CONTACT_1196], Preferred Term and Dose 
Group Dose Escalation Segment   Dose Escalation  Safety Analysis Set  ......................  47 
Table [IP_ADDRESS] Summary of Drug -related TEAEs by [CONTACT_1196], Preferred Term 
and Dose Group Dose Esc alation Segment   Dose Escalation Safety Analysis Set  ...... 48 
Table [IP_ADDRESS] Summary of TEAEs Leading to Study Discontinuation by [CONTACT_480350], Preferred Term and Dose Group Dose Escalation Segment   Dose Escalation 
Safety Analysis Set  ................................ ................................ ................................ ....... 48 
Table [IP_ADDRESS] Su mmary of Serious TEAEs by [CONTACT_1196], Preferred Term and 
Dose Group Dose Escalation Segment   Dose Escalation Safety Analysis Set  .............  48 
Table [IP_ADDRESS] Summary of TEAEs by [CONTACT_480351] -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  49 
Table [IP_ADDRESS] Summary of TEAEs by [CONTACT_480352]  ................................ ................................ ............  50 
Table 14.3 .1.13 Clinical Laboratory Evaluations in Biochemistry (Observed Values)  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  51 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 6 of 100 Table [IP_ADDRESS] Clinical Laboratory Evaluations in Change from Baseline in Biochemistry  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  52 
Table [IP_ADDRESS] Biochemistry Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 53 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Hematology (Observed Values)  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Change from Baseline in Hematology  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table [IP_ADDRESS] Hematology Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 54 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Urinalysis (Observed Values)  Double -
blind Segment   Double -blind Safety Analysis Set  ................................ ........................  54 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Change from Baseline in Urinalysis 
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table [IP_ADDRESS] Urinalysis Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 55 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Biochemistry (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  56 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Hematology (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  57 
Table [IP_ADDRESS] Clinical Laboratory Evaluations in Urinalysis (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  57 
Table [IP_ADDRESS] Summary of Vital Signs (Observed Values) Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  58 
Table [IP_ADDRESS] Summary of Vital Signs in Change from Baseline  Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  59 
Table [IP_ADDRESS] Summary of Vital Signs (Observed Values)  Dose Escalation Segment   
Dose Escalation Safety Analysis Set  ................................ ................................ ............  60 
Table [IP_ADDRESS] Summary of 12 -Lead ECG (Observed Values)  Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  61 
Table [IP_ADDRESS] Summary of 12 -Lead ECG in Change from Baseline  Double -blind 
Segment   Double -blind Safety Analysis Set  ................................ ................................ . 62 
Table [IP_ADDRESS] Summary of 12 -Lead ECG (Observed Values)  Dose Escalation Segment   
Dose Escalation Safety Analysis Set  ................................ ................................ ............  63 
Table [IP_ADDRESS] Summary of Fasting Plasma Glucose by [CONTACT_4838] (Observed Values)  Double -
blind Segment   Double -blind Safety Analysis Set  ................................ ........................  64 
Table [IP_ADDRESS] Summary of Concomitant Medication Double -blind Segment   Double -
blind Safety Analysis Set  ................................ ................................ ..............................  65 
Table [IP_ADDRESS] Summary of Concomitant Medication Dose Escalation Segment   Dose 
Escalation Safety Analysis Set  ................................ ................................ .....................  66 
 
Listings:  
 
Listing 16.2.[ADDRESS_617348] Disposition  ................................ ................................ .........................  68 
Listing 16.2.2 Protocol Deviations  ................................ ................................ ........................  69 
Listing 16.2.3 Subjects Excluded from the Efficacy Analysis (Double -blind Segment)  ..........  70 
Listing [IP_ADDRESS] Demographics  ................................ ................................ .............................  71 
Listing [IP_ADDRESS] Medical History  ................................ ................................ ............................  72 
Listing [IP_ADDRESS] Prior and Concomitant Medication  ................................ ...............................  73 
Listing [IP_ADDRESS] Inclusion/Exclusion Criteria and Exceptions  ................................ ................  74 
Listing [IP_ADDRESS] Urine Drug Screen  ................................ ................................ .......................  75 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 7 of 100 Listing 16.2.5 Study Drug Administration  ................................ ................................ ..............  76 
Listing [IP_ADDRESS] Fasting Plasma Glucose (mg/dL)  ................................ ................................  77 
Listing [IP_ADDRESS] Weight  ................................ ................................ ................................ .........  78 
Listing [IP_ADDRESS] Glycated Hemoglobin A1 (HbA1c) (%)  ................................ ........................  79 
Listing [IP_ADDRESS] 24 h UGE (g/day)  ................................ ................................ ........................  80 
Listing [IP_ADDRESS] Blood (PK) Sample Collection (Dose Escalation Segment)  .........................  81 
Listing [IP_ADDRESS] Post Pr andial Blood Glucose (mg/dL) (Dose Escalation Segment)  ..............  82 
Listing [IP_ADDRESS] Treatment Emergent Adverse Events  ................................ ..........................  83 
Listing [IP_ADDRESS] Drug -related Treatment Emergent Adverse Events  ................................ ..... 84 
Listing [IP_ADDRESS] Serious Treatment Emergent Adverse Events  ................................ .............  84 
Listing [IP_ADDRESS] Treatment Emergent Adverse Events Leading to Study Discontinuation  ..... 84 
Listing [IP_ADDRESS] Cardiovascular Treatment Emergent Adverse E vents  ................................ . 84 
Listing [IP_ADDRESS] Pre -treatment Adverse Events  ................................ ................................ ..... 85 
Listing [IP_ADDRESS] Adverse Events during Washout Period  ................................ ......................  86 
Listing [IP_ADDRESS]  Clinical Laboratory Test Results in Biochemistry  ................................ .........  87 
Listing [IP_ADDRESS] Clinical Laboratory Test Results in Hematology ................................ ...........  88 
Listing [IP_ADDRESS] Clinical Laboratory Test Results in Urinalysis  ................................ ..............  88 
Listing [IP_ADDRESS] Vital Signs  ................................ ................................ ................................ ... 89 
Listing [IP_ADDRESS] 12 -Lead ECG  ................................ ................................ ..............................  90 
Listing [IP_ADDRESS] Self Monitored Blood Glucose (SMBG)  ................................ .......................  91 
Listing [IP_ADDRESS] Physical Examination  ................................ ................................ ..................  92 
 
Figures:  
 
Figure 14.2.1 Fasting Plasma Glucose (mean± SE) - Double -blind Segment  .......................  94 
Figure 14.2.2 Fasting Plasma Glucose in Change from Baseline (mean± SE) - Double -
blind Segment  ................................ ................................ ................................ ...............  95 
Figure 14.2.3 Body Weight (mean± SE) - Double -blind Segment  ................................ .........  96 
Figure 14.2.4 Body Weight in Change from Baseline (mean± SE) - Double -blind Segment  .. 96 
Figure 14.2.5 HbA1c (mean± SE) - Double -blind Segment  ................................ ...................  97 
Figure 14.2.6 24h UGE (mean± SE) - Double -blind Segment  ................................ ...............  98 
Figure 14.2.7 Mean Plasma Concentration for EGT0001442 (ng/mL) - Dose Escalation 
Segment  ................................ ................................ ................................ .......................  99 
Figure  14.2.8 Individual Plasma Concentration for EGT0001442 (ng/mL) - Dose Escalation 
Segment  ................................ ................................ ................................ .....................  100 
 
  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 8 of 100 Statistical Analysis Plan  
1. INTRODUCTION  
This SAP is based on the final Protocol THR-1442 -C-402 Amendment 2 dated 23 
February  2010 . The SAP provides details on the planned statistical methodology for 
analysis of  the study data. The SAP also outlines the statistical programming 
specifications for the tables, listings and figures.   
 
This SAP describes the study endpoints, derived variables, anticipated data 
transformations  and manipulations, and other details of the analyses not provided in the 
study protocol. This SAP therefore outlines in detail all other aspects pertaining to the 
planned analyses and presentations  for this study .  
 
The following documents were reviewed in preparation of this SAP:  
 Clinical Research Protocol final Protocol THR -1442 -C-402 Amendment 1 dated 23 
February  2010  
 Case report forms (CRFs) issued on 22 March  2010: R09 -0980  (THR -1442 -C-402) 
eCRF Template - Insubject  V1.2.pdf and R09 -0980  (THR -1442 -C-402) eCRF 
Template - Outsubject  V1.2.pdf 
 ICH Guidance on Statistical Principles for Clinical Trials.  
 
The reader of th is SAP is encouraged to also read the clinical protocol for details on the 
conduct of this study, and the operational aspects of clinical assessments and timing for 
completing a subject  in this study.  
 
2. OBJECTIVES   
Primary Objective s: 
 
The primary objectives of this study are:  
 
 To determine the effect of EGT0001442 on fasting plasma glucose (FPG) at the 
end of 4 weeks of treatment.  
 To assess the pharmacokinetics and safety and tolerability of EGT0001442 at four 
dose levels in diabetic subjects given the drug daily for 4 weeks.  
 
 
Secondary  Objective s: 
 
 To determine changes in body weight at week 4 from baseline.  
 To determine changes in HbA1c at week 4 compared to baseline.  
 To determine changes in FPG following cessation of treatment  
 To determine the pharmacodynamics of EGT0001442 by [CONTACT_480353] 
(UGE) in diabetic subject s on day 0, day 1 and day 28.  
 
PK Objective:  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 9 of 100  
 To determine the pharmacokinetics of EGT0001442 in diabetic subject s 
 
Exploratory Objective:  
 
 To measure changes in post -prandial blood glucose from baseline to day [ADDRESS_617349] s in the dose escalation segment of the trial while they remain 
supervised in the clinic.  
 
3. OVERALL STUDY DESIGN  AND PLAN  
EGT0001442 is an experimental agent being developed by [CONTACT_480354]. for the treatment 
of type 2 diabetes.  EGT0001442 is a selective inhibitor of human sodium glucose 
cotransporter 2 (SGLT2).  A first -in-human study and a subsequent phase I study in 
diabe tic subject s have previously evaluated the safety and tolerability of EGT0001442 (as 
proline cocrystal) up to a dose of 100 mg/d for 14 days (150 mg/d of cocrystal) in healthy 
volunteers or as a single dose of 100 mg (150 mg of cocrystal) in diabetic subject s. This 
trial is the first to expose human subject s to EGT0001442 as a single agent (i.e., not as 
proline cocrystal) and is conducted at dose levels of 5, 10, [ADDRESS_617350] 
will review the outco mes and pharmacokinetic data to determine if the pharmacokinetic 
profile will result in the mean C max or AUC 0-24 exceeding the NOAEL in male rats (the 
limiting sex and species derived from 28 day repeat dosing studies).  
The second segment of the proposed clinical evaluation is a multicenter, placebo -
controlled, five -arm parallel group, double -blind, randomized clinical trial of [ADDRESS_617351] s per dose for 
a period of 28 days followed by a 14 day follow -up period.  
The primary objective of the second segment is to evaluate the efficacy of EGT0001442 in 
the treatment of type 2 diabetes mellitus. A pproximately 125 subjects will be randomly 
assigned to receive EGT0001442 at 5, 10, 20, or 50 mg/day or placebo with an equal 
number of subjects per group.  
The primary efficacy end point is the assessment of the effect of EGT0001442 on fasting 
plasma gluco se (FPG) after 4 weeks on treatment compared to baseline FPG values. The 
secondary efficacy end points include:  
 
•   Changes in body weight at week 4 from baseline  
•   Changes in HbA1c at week 4 compared to baseline  
•   Change in FPG following cessation of treatment  
•   Pharmacodynamic effects of EGT0001442 on urinary glucose excretion (UGE) in    
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 10 of 100     diabetic subjects on day 0 (baseline), day 1 and day 28.  
 
Safety of EGT0001442 will be evaluated by [CONTACT_480355] e events and 
concomitant medication records, hematology and blood chemistry laboratory results, 
cardiovascular events, electrocardiograms (ECG), urine electrolytes and urinalysis.  
PK parameters will be evaluated in the [ADDRESS_617352]  randomization segment, the following treatments will be administered:  
Table  1.  EGT0001442  or placebo treatments   
Treatment group  Placebo  
capsule /day  EGT0001442  
capsules /d ay Total # 
capsules/day  [ADDRESS_617353] s in the upright position with approximately 200 mL of water between 07:00 h 
and 10:[ADDRESS_617354] from the DSMB will be allowed to 
receive unblinded data.  
To manage the safety monitoring and maintain blinding of the treatment, there will be an 
unblinded study staff who will review the FPG data a nd alert the investigator  and essential 
study staff if glucose is below 2.8 mmol/L (50 mg/dL), 3.9 mmol/L (70 mg/dL), or above 12 
mmol/L (216 mg/dL), 15 mmol/L (270 mg/dL) or 16.7 mmol/L (300 mg/dL). The actual 
numerical values of the FPG will remain blind ed to all study personnel and subject s unless 
clinically indicated, as outlined in section 5.4.  
The investigator will also receive a sealed envelope for each subject  containing a 
description of the dispensed medication.  The envelope can be opened only if  knowledge 
of the test substance is needed to manage the subject ’s condition.  If opened, the date of 
opening and the reason for opening must be written on the envelope. At the conclusion of 
the study, all envelopes must be returned to the Sponsor. These w ill be checked to ensure 
that the seals had not been broken, unless warranted by [CONTACT_480356].  If unblinding occurs, the time and reason for unblinding will be recorded 
on the CRF and the sponsor must be notified within [ADDRESS_617355] s who complete the 1 5 ± [ADDRESS_617356] research organization (CRO). Approximately 
[ADDRESS_617357] s are assigned to placebo or 
EGT0001442 at doses of 5, 10, 20, or 50 mg/day in a 1:1:1:1:[ADDRESS_617358] s at each site. Enrollment will be on a 
competitive basis but will be capped at 40% of the total randomized subject s ([ADDRESS_617359] s) 
from one center.  
7. SAMPLE SIZE  
The efficacy pairwise null and alternative hypotheses to be assessed are as follows:  
H0i: μi = μ P 
vs. 
H1i: μi ≠ μ P 
 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 12 of 100 where  μi = the mean change in FPG from baseline to week 4  for dose i (i = 5, 10, 20 or 50 
mg/day of EGT0001442) and  μP = the mean change in FPG from baseline to week [ADDRESS_617360] of each pairwise null hypothesis will be carried out at the two -sided 0.05 
level of significance; no adjustment for multiple comparisons will be made.  
 
The sample size of [ADDRESS_617361] s per group was calculated based on the following 
assumptions:  
1. Baseline mean (± standard deviation) FPG is 190 (± 40) mg/dL for each dose 
group;  
2. The active doses will decrease FPG on average by 25 (± 25 ) mg/dL from baseline 
to day 28  
3. The placebo will not experience a substantive average decrease in mean F PG from 
baseline to day 28; the standard deviation of the change in mean FPG from 
baseline to day 28 is assumed conservatively to be 25 (same standard deviation as 
for active doses).  
4. The two -sided significance level for each pairwise hypothesis is 0.05.  
 
Under the above assumptions, an evaluable sample size of [ADDRESS_617362] s per 
treatment arm yields approximately 90% power that at least one dose will be found to be 
significantly different from placebo.  A sample size of [ADDRESS_617363]-to-follow -up. 
8. ANALYSIS POPULATION S 
Intent -to-Treat Analysis Set:    
All randomized subjects in segment [ADDRESS_617364] s will be analyzed according to the 
treatment to which they were randomized.  The Intent -to-Treat Analysis Set will be used to 
perform the efficacy analysis for the double -blind segment  only.   
 
Per-Protocol Analysis Set:   
The subset of subject s from the Int ent-to-Treat analysis set that received at least [ADDRESS_617365] any major protocol deviations and were measured 
for FPG visit with confirmed ≥[ADDRESS_617366]  evaluability will be performed prior 
to breaking treatment codes and locking the database.  
Double -blind Safet y Analysis Set:   
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617367] s will be analyzed according to the treatment received.  
The Double -blind Safety Analysis Set will be used to perform  safety assessment s for the 
double -blind segment . 
Dose -Escalation Safety Analysis Set:    
All subject s who receive at least one dose of treatment during the dose escalation 
segment of the study. Subject s will be analyzed according to the treatment received.   
The Dose -Escalation Safety Analysis Set will be used to perform safety assessment s for 
the open -label dose escalation segment .  
9. STUDY ENDPOINTS  
Primary Efficacy Endpoint  
The primary efficacy endpoint is change in FPG.   
Secondary Efficacy Endpoints  
 Change in body weight from baseline to day 29  
 Change in HbA1c from baseline to day 29.  
 Change in FPG from cessation of treatment (days 27/29 to days 41/43).  
 24 h UGE on day 0, day 1 and day 28  
Primary Safety Endpoints  
 Adverse events  
 Clinical  and laboratory variables  
 Concomitant medication   
 FPG, Vital signs , SMBG record, and ECG parameters   
 
10. STATISTICAL METHODS  
Data will be summarized  with respect to demographic and baseline characteristics, 
efficacy variables and safety variables.  
Summary statistics will include the mean, N, standard deviation, median, minimum, and 
maximum values for continuous variables, and frequencies and percentages for 
categorical variables.  
If not otherwise specified, all statistical analyses will be two -sided and the Type I (alpha) 
error is fixed at the 5% level.  
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617368] deviation, minimum and maximum; categorical measures will be 
presented with the counts  and percents of subject s in each category.  No statistical tests 
comparing treatments at baseline will be performed.   
Age is  calculated in years after rounding down as follows:  
Year of age = (Date inform ed consent signed  - Date of birth ) / 365.[ADDRESS_617369]  in 
the dose escalation segment.  
10.1. 3 Inclusion/ Exclusion  Criteria and Exceptions  
Subject  inclusion/exclusion criteria and exceptions will be listed by  [CONTACT_472786], 
treatment group and subject  in the double -blind segment and by [CONTACT_472786], dose and 
subject  in the dose escalation segment.  
10.1. [ADDRESS_617370] listings.  
Response Variable and Baseline : 
The primary efficacy endpoint of change in FPG  will be treated as the response 
variable . FPG will be determined from the blood samples drawn at baseline, defined as 
the mean of FPG values on day -2 and day 1 and af ter 4 weeks of treatment, defined 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 15 of 100 as the mean of FPG values on day 27 and day 29. If one of the two FPG values at 
baseline or at 4 -week treatment is missing, the single value available will be used.  If 
both values are missing (either baseline or at the 4 -week treatment), this data will not 
be used.  
Descriptive Summary:  
Descriptive statistics (sample size, mean, median, standard deviation, minimum and 
maximum) of the primary endpoint will be presented for each treatment group.  In 
addition, descriptive statis tics of the baseline and after 4 weeks of treatment values will 
be presented.  
ANCOVA Model:  
Pairwise comparisons of each active dose versus placebo on mean change in FPG 
from baseline will be carried out at the two -sided 0.05 alpha level of significance us ing 
analysis of covariance adjusting for study center and baseline FPG. Baseline FPG and 
center will be treated as covariate. The pairwise differences in mean change in FPG 
means between each dose and placebo, and its associated two -sided 95% confidence 
interval, adjusted for study center and baseline FPG will be presented.  
Assessment  of Interactions:  
The interactions of treatme nt-by-baseline and treatment -by-center will be assessed in 
two separate models  using [ADDRESS_617371] at the 0.10 level of s ignificance or a significant 
interaction that is only quantitative and not qualitative in nature (i.e. where the 
treatment effect differs only in magnitude but not direction across study centers) will 
support the pooling of subject s across study centers fo r purposes of the primary 
analysis pairwise comparisons. Centers with less than 5 subjects  randomized  will be 
pooled into one or more centers based on the geographic regions .  
Missing Data:  
No imputation will be carried out for missing data with the exception of subject s who 
ended treatment due to rescue medication. For such subject s, the last FPG value 
measured prior to the subject  receiving rescue medication will be carried forward to 
day 2 9.  
10.3 Secondary  Analyse s 
Analysis for the secondary endpoints will be carried out in a similar manner as for the 
primary efficacy endpoint of FPG. The change in FPG following cessation of treatment 
will be determined from the blood samples drawn at week  4 of treatment, defined as 
the mean of FPG values on day 27 and day 29 to week 6, defined as the mean of FPG 
values on day 41 and day 43. No imputation will be carried out for missing data. Due to 
the secondary nature of these outcomes, no assessments of the treatment -by-center 
interaction will be carried out, unless  a significant qualitative treatment -by-center 
interaction is found for FPG. The interaction of treatment -by-baseline, however, will be 
carried out on all secondary analyses where baseline is m easured.  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 16 of 100 Baseline for weight is defined as the pre -dose weight value on Day 1 at Visit 5. 
Baseline for HbA1c is defined as the pre -dose  HbA1c value on Day 1 at Visit 5. 
Baseline for 24h UGE is defined as the pre -dose UGE value on Day 0 at Visit 4.  
If the safety and ITT analysis sets  differ by [CONTACT_726] 10%, the analysis on UGE will 
also be conducted on the safety analysis set . 
10.[ADDRESS_617372] s in the dose escalation study where 
applicable. Results will be presented by [CONTACT_1570]/dose group.  
For repeat safety assessments  (clinical laboratory tests , vital signs and ECGs),  the 
following will apply for the summary tables.   
 Repeat safety assessments prior to dosing, the repeated values will be used for 
calculations but all values will be included in the listings.  
 Repeat safety  assessments after dosing, the original values will be used but all values 
will be included in the listings.   
10.4.1 Adverse Event Analysis  
Adverse events will be mapped  using the Medical Dictionary for Regulatory Activities 
(MedDRA) central coding dictionary  (version  12.1).  Each adverse event is to be evaluated 
for date/time of onset, duration, severity  and causal relationship with the study drug or 
other factors.   
Treatment Emergent Adverse Events  
Treatment Emergent A dverse Events (TEAEs) are any AEs that start or worsen at or 
after administration of the first dose of study medication.  
Adverse Event listings will be provided for all TEAEs, all drug -related TEAEs, serious 
TEAEs, and any TEAEs leading to study discontinuation.  
The number and percentage of subject s experiencing TEAEs will be summarized by 
[CONTACT_480357]. Each 
subject  will be counted only once within each preferred term. If the same AE occurs in 
a subject  on multiple occasions, the highest severity and least complementary 
relationship will be assumed. If two or more AEs are reported as a single event, the 
individual terms will be reported as separate AEs.  
This analysis will be repeated for drug -related an d serious TEAEs and for TEAEs 
leading to study discontinuation.  
TEAEs will also be tabulated by [CONTACT_480358].  
No formal statistical tests comparing treatment groups will be performed.  
Adverse Events  during Washout Period  
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617373]  listings  by [CONTACT_480359], treatment /dose  group and subject . 
Descriptive statistics (sample size, mean, median standard deviation, minimum, and 
maximum) of the continuous variables at each visit will be summarized for both 
double -blind segment and dose escalation segment by [CONTACT_3148]/dose group.  
Change from  baseline to each visit will be presented  for double -blind segment . 
Baseline is defined as the laboratory value prior to dosing. A paired t -test assessing 
the significance of the change from baseline will be presented for each variable within 
each treatmen t group.   
Shift tables displaying the change in normality status from baseline to post -baseline 
visits will be presented  for the double -blind segment .  
10.4.3 Concomitant Medication  
Concomitant medications will be coded using the World Health Organization Dictionary 
(WHOD rug Version 101E).  A table of concomitant medications based on the anatomic 
therapeutic chemical classification (ATC) and preferred name [CONTACT_480366] 
[CONTACT_3148]/dose group .  
A listing of concomitant medications will include all medica tions taken during the 
course of the study.  
Any medications taken prior to the start of the study medication will be listed and 
summarized in a similar manner.  
No formal statistical tests comparing treatment groups will be performed.  
10.4.[ADDRESS_617374], and ECG Parameters  
Vitals signs including pulse, systolic and diastolic blood pressure at sitting position, 
respi[INVESTIGATOR_1487], and temperature will be measured at screening, prior to dosin g, and at 
each follow up visit. 
A 12 -lead electrocardiogram (ECG) will be conducted at screening, prior to dosing, 
and at each follow up visit.  
Fasting plasma glucose, vital signs and ECG parameters will be listed and presented 
in a similar manner as for clinical laboratory tests  above.   
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617375]  listings.  
10.4.5 Physical Exam  
A complete physical examination will be performed at screening and at the termination 
visit. A complete physical examination will include measurement of body weight and heig ht 
(height will be measured only at screening), general assessment of all body systems 
(except genitals) including the skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, 
heart, abdomen, lymph nodes, and extremities. A partial physical examination will include 
body weight and general assessment of the skin, heart, lungs and abdomen.  
Physical exam will be listed by [CONTACT_472786], treatment group and subject  in the double -
blind segment and by [CONTACT_472786], dose and subject  in the dose escalation segment.  
10.[ADDRESS_617376].  
 
Subjects who experience emesis will be treated according to Cetero Resea rch SOP 
entitled “Handling Subjects Experiencing Emesis Epi[INVESTIGATOR_1865](s) in BA/BE Studies.”  Although 
the SOP's scope is specified as for BA/BE studies, it will be adopted for the analysis of this 
study, where applicable.  Subjects vomiting within 6.6 hours after  drug administration will 
be dropped from the study (based on 2 times the a priori mean population Tmax of 3.3 
hours). Their samples will be analyzed by [CONTACT_480360] . 
 
Concentration v alues below the lower limit of quantification (BL Q) will be treated according 
to Cetero Research SOP entitled  “Handling BLQ data in PK/PD studies”.  Subjects with 
BLQ values between two non -BLQ concentrations will be set to missing.   BLQ values that 
occur at the beginning on the profile will be set to zero.  
 
Data from subjects with missing concentration values (missed blood draws, lost samples, 
samples unable to be quantitated) may be used if pharmacokinetic parameters can b e 
estimated using the remaining data points. Otherwise, concentration data from these 
subjects will be excluded from the final analysis.  
 
A non -compartmental pharmacokinetic analysis (SAS, Cary, NC or WinNonlin 5.0.1, 
Pharsight Corp., Mountain View, CA, US A) will be used to calculate the PK parameters for 
each subject . The actual time of sample collection will be used in the PK parameters 
calculations . 
 
 Cmax Maximum observed plasma concentration  
 Tmax Time of observed  maximum plasma concentration  
 Kel        Terminal phase rate constant  
 Thalf        Apparent terminal half life  
 CL/F  The apparent total body clearance  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 19 of 100  Vz/F The apparent total volume of distribution  
 AUC 0-t  Area under the plasma concentration -time curve from Time 0 to Time t  
 (time of last quanti fiable plasma concentration)  
 AUC 0-inf  Area under the plasma concentration -time curve from Time 0 to infinity  
 AUC 0-24  Area under the plasma concentration -time curve from Time 0 to 24 h  
 
Descriptive statistics ( arithmetic mean, standard deviation [sd], median, minimum , 
maximum , coefficient of variation ) will be summarized by [CONTACT_480361] -AUC 0-t, ln-AUC 0-24, ln-AUC 0-inf and ln -Cmax. Additionally, geometric 
means will be calculated for AUC 0-t, AUC 0-24, AUC 0-inf and C max.  
No value of Kel, AUC 0-inf, Thalf,  CL/F , or Vz/F will be reported for cases that do not exhibit 
a terminal log -linear phase in the concentration versus time profile.  
 
Other pharmacokinetic parameters may be calculated if deemed necessary.  
10.[ADDRESS_617377] s in the dose escalation phase of the trial.  
Measurements will be taken before each meal (breakfast, lunch, and dinner) and then 2 
hour after meal completion. A seventh measurement will be taken at 10 pm (
 30 mins) at 
night.  
The difference between the post -meal measurement and the measurement before the 
same meal will be identified as the post -prandial glucose change for that meal.    For each 
meal, the difference in day [ADDRESS_617378] (DSMB) will inspect the safety data from the dose escalation 
segment, review SAE reports, and will periodically inspect unblinded safety data from the 
double -blind study.  A DSMB charter will be written outlining the safety data to  be 
inspected periodically by [CONTACT_4318].  
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617379] of this study but are intended to show the general 
layout of the Table s, Listings and Figures that will be included in the final report. Tables 
and listings are numbered following the ICH structure. Table headers, variables names 
and footnotes will be modified as needed following data analyses. Ple ase note that all 
summary tables  and listings  will be generated using SAS® Version 9.1.3.  Figures w ill be 
generated using SigmaPlot Version 10  and/or SAS® Version 9.1.[ADDRESS_617380] s (Double -blind Segment ) 
     
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
                ______________________________________________ ______________________   
       
           EGT0001442      EGT0001442   EGT0001442     EGT0001442  
        Placebo  5 mg           10 mg   20 mg  50 mg         Overall           
         (N=xx)        (N=xx)         (N=xx)   (N=xx)        (N=xx)         (N=xx)                                 
____________________________________________________________________________________________________________ _______________________________  
 
Number of subjects randomized (N)    xx  xx             xx     xx      xx        xx      
Included in Double-blind Safety Analysis Set  [n (%)] xx(xx.x%)      xx(xx.x%)       xx(xx.x%)   xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
Included  in Intent -to-Treat Analysis Set  [n (%)] xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)  xx(xx.x%)   xx(xx.x%)  
Included  in Per-Protocol Analysis Set  [n (%)]  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)  xx(xx.x%)   xx(xx.x%)  
Included in Completed study [n (%)]             xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  xx(xx.x%)                                            
Discontinued from study [n (%)]                  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                          
Reason for Discontinuation                      
   Discontinued due to Adverse Event [n ( %)]       xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                             
   Subject elected to withdraw from stud y [n (%)]       xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                          
 Death [n (%)]                    xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                         
 Study terminated by [CONTACT_3211] [n (%)]                 xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                          
  Investigator decision [n (%)]                        xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                           
   Lost to follow -up [n (%)]                      xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%) 
 Poor Glycemic Control [n (%)]                      xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)  xx(xx.x%)                                       
 Other [n (%)]                                  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                
_____________________________________________________________________________________________________________________________ ______________  
N: Number of subjects randomized  in the s pecified treatment group 
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617381] s (Dose Escalation S egment)  
     
 
_____________________________________________________________________________________________________________________________ _____________  
                                      
                    Dose Group  
         _________________________________________ __________________________ ______  
      
         EGT0001442         EGT0001442   EGT0001442    EGT0001442  
        5 mg           10 mg  20 mg           50 mg        Overall              
         (N=xx)            (N=xx)  (N=xx)    (N=xx)    (N=xx)                                   
______________________________________________________________________________________________________________ ____________________________  
 
Number of subjects enrolled (N)     xx     xx              xx     xx            xx        
Included in Dose -Escalation Safety Analysis Set  [n (%)] xx(xx.x%)         xx(xx.x%)       xx(xx.x%)   xx(xx.x%)    xx(xx.x%)  
Included in Completed study [n (%)]             xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
Discontinued from study [n (%)]                  xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
Reason for Discontinuation                      
   Discontinued due to Adverse Event [n (%)]       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                                
   Subject elected to withdraw from study [n (%)]       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
 Death [n (%)]                    xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
 Study terminated by [CONTACT_3211] [n (%)]                 xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
  Investigator decision  [n (%)]                       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
   Lost to follow -up [n (%)]                      xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
 Other [n (%)]                                  xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                       
   
______________________________________________________ _________________________________________________________ __________________________  
N: Number of subjects enrolled  in the specified  dose group 
n: Number of subjects                      
%: Percentage based on N 
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 24 of 100 Table 14.1. 3 Summary of Demographics  (Double -blind Segment ) 
     
 
___________________________________________________________________________________________ _________________ ____________________  
                                      
                 Treatment Group   
             _______________________________________________________________ ______________    
       
              EGT0001442       EGT0001442  EGT0001442     EGT0001442  
      Placebo        5 mg           10 mg  20 mg       50 mg          Overall           
Parameter    Statistic  (N=xx)       (N=xx)        (N=xx) (N=xx)         (N=xx)     (N=xx)                                
_______________________ _____________________________________________________________________________________ _____________________  
 
Age (years)   n              xx             xx             xx                xx         xx       xx                     
                        Mean ± SD xx ± x.x  xx ± x.x   xx ± x.x   xx ± x.x    xx ± x.x   xx ± x.x  
                        Median         xx             xx             xx                xx         xx       xx                     
    Min , Max      xx , xx  xx , xx  xx , xx  xx , xx   xx , xx  xx , xx 
                                                                                                                                                  
Height (cm)               n  xx             xx             xx                xx   xx         xx                   
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x    xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
                                                                                                                                                  
Weight (kg)             n  xx             xx             xx                xx   xx        xx                    
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x   xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
                      
BMI (kg/m^2)    n  xx             xx             xx                xx   xx          xx                  
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x    xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
 
___________________________________________________________________________________________________________ ______________________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
SD: Standard Devi ation 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 25 of 100 Table 14.1. 3 Summary of Demographics ( Double -blind Segment ) (continued)  
 
_______________________________________________ ___________________________________________________________________________________________  
 
                                                    Treatment Group   
        _________________________________________________________________ ________  
        
               EGT0001442       EGT0001442  EGT0001442  EGT0001442  
       Placebo  5 mg             10 mg          20 mg  50 mg          Overall           
Parameter         Statistic  (N=xx)        (N=xx)          (N=xx)          (N=xx)     (N=xx)         (N=xx)                                
___________________________________________________________________________________________________________________________ ______________  
 
Race      [n (%)]                          
   American Indian / Alaska Native   xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)     xx(xx.x%)                                             
   Asian      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)      xx(xx.x%)                                          
 Black / African American    xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)     xx(xx.x%)                                           
 Native Haw aiian / Other Pacific Islander  xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)      xx(xx.x%)                                          
  White      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
                                            
Gender     [n (%)]                          
   Male      xx(xx.x%)       xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)    xx(xx.x%)                                              
   Female      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
 
Ethnicity      [n (%)]                          
   Hispanic or Latino                           xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)    xx(xx.x%)                                               
   Not Hispanic or Lat ino                       xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)    xx(xx.x%)                                            
                                            
___________________________________________________________________________________________________________ ________________ ______________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 26 of 100 Table 14.1. 4 Summary of Demographics (Dose Escalation Segment)  
     
 
______________________________________________________________________________________________________________________ __________  
                                     
                  Treatment Group   
              _________________________________________ _______________________    
       
             EGT0001442     EGT0001442    EGT0001442  EGT0001442  
            5 mg           10 mg         20 mg           50 mg          Overall 
Parameter        Statistic       (N=xx)      (N=xx)        (N=xx)   (N=xx)         (N=xx)                
____________________________________________________________________________________________________________ ____________________  
 
Age (years)    n                   xx             xx             xx             xx           xx                  
                        Mean ± SD           xx ± x.x  xx ± x.x   xx ± x.x   xx ± x.x   xx ± x.x  
                            Median              xx             xx             xx             xx           xx 
                           Min , Max           xx , xx  xx , xx  xx , xx  xx , xx  xx , xx 
                                                                                                                                                  
Height (cm)                 n                   xx             xx             xx             xx            xx                 
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , xx.x  xx.x , xx.x   xx.x , xx.x  xx.x , xx.x    xx.x , xx.x                                 
                                                                                                                                                  
Weight (kg)             n                   xx             xx             xx             xx            xx                 
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , x x.x xx.x , xx.x   xx.x , xx.x  xx.x , xx.x    xx.x , xx.x                
                      
BMI (kg/m^2)     n                   xx             xx             xx             xx             xx               
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , xx.x  xx.x , xx.x   xx.x , xx.x  xx.x , xx.x     xx.x , xx.x               
_____________________________________________________________________________________________________________________ _____________  
N: Number of subjects enrolled in the specified dose group  
n: Number of subjects                      
SD: Stand ard Deviation  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 27 of 100 Table 14.1. 4 Summary of Demographics (Dose Escalation Segment) (continued)  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group    
           ___________________________________ __________________ _______________     
               EGT0001442      EGT0001442   EGT0001442  EGT0001442  
              5 mg            10 mg              20 mg          50 mg          Overall 
Parameter        Statistic          (N=xx)        (N=xx)  (N=xx)        (N=xx)         (N=xx)               
____________________________________________________________________________________________________________ _____________________________  
 
Race        [n (%)]                          
   American Indian / Alaska  Native   xx(xx.x%)      xx(xx.x%)  xx(xx.x%)   xx(xx.x%)    xx(xx.x%)                                              
   Asian       xx(xx.x%)  xx(xx.x%)         xx(xx.x%)     xx(xx.x%)     xx(xx.x%)                                           
 Black / African American     xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)    xx(xx.x%)                                            
 Native Hawaiian / Other Pacific Islander   xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)    xx(xx.x%)                                            
  White       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)  
                                            
Gender            [n (%)]                          
   Male       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                               
   Female       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)  
 
Ethnicity             [n (%)]                          
   Hispanic or Latino                                 xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                               
   Not Hispanic or Latino                             xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                             
                                            
____________________________________________________________________________________________________________________ ____________________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 28 of 100 Table 14.2.1 Primary Efficacy Analysis: Descriptive Summary of  Fasting Plasma Glucose  from Baseline  to End of Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _________ ____ 
 
                                                     Treatment Group   
       _____________________________________________________________________________________  
 
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                 Placebo         5 mg            10 mg             20 mg       50 mg                   
                          Statistic      (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx) 
_____________________________________________________________________________________________________________________________ _________ ____ 
 
Baseline *           n               xx               xx               xx      xx                xx       
                   Mean ± SD       xx.x ± x.xx      xx.x  ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                            Min, Max        xx , xx          xx , x x          xx , xx   xx , xx           xx , xx  
 
End of Treatment #                n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx           
 
Change from Baseline to          n               xx               xx               xx      xx                xx                                                          
End of Treatment    Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx  
  
_____________________________________________________________________________________________________________________________ _________ ____ 
Note: * Baseline is defined as the mean of FPG values on day -2 and day 1. 
      # End of Treatment is  defined as the mean of FPG values on day 27 and d ay 29. 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 29 of 100 Table 14.2.2 Primary Efficacy Analysis: ANCOVA Results on Mean Change in FPG from Baseline  to End of Treatment  
Double -blind Segment  
Intent -to-Treat  Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatment s  
                    ________________________________________________                                       
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
____________ _____________________________________________________________________________________________________________________________ _ 
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
_____________________________________________________________________________________________________________________________ ____________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and base line and center  as covariate s. P-values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the mean of FPG values on day -2 and day 1. 
      End of T reatment is  defined as the mean of FPG values on day 27 and d ay 29. 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 30 of 100 Similar tables:  
 
 
Table 14.2. [ADDRESS_617382] Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                     Treatment Group   
       _____________________________________________________________________________________  
 
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                 Placebo         5 mg             10 mg             20 mg       50 mg                   
                          Statistic      (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
______________________________ ____________________________________________________________________________________________________________  
 
End of Treatment#                n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx           
 
Post Treatment+    n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx                                      
 
Change from End of Treatment to  n               xx               xx               xx      xx                xx                                                          
Post Treatment    Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx                    
____________________________________________________________________________ ______________________________________________________________  
Note: # End of Treatment is  defined as the mean of FPG values on day 27 and d ay 29. 
      + Post T reatment is determined from the blood samples drawn at week 4 of treatment, defined as the mean  of FPG values on day 27 and  
        day 29 to week 6, defined as the mean of FPG values on day 41 and day 43.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
                                                               
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617383] Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_____________________________________________________________________________________________________________________________ _____________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs . Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
__________________________________________________________________________________________________________________________ _______________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans , 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: End of Treatment is  defined as the mean of FPG values on day [ADDRESS_617384] Treatment is determined from the blood samples drawn at week 4 of treatment, defined as the mean of FPG values on day 27 and  
      day 29 to week 6, defined  as the mean of FPG values on day 41 and day 43.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 33 of 100 Table 14.2. 7 Descriptive Summary of Change in Body Weight  from Baseline to Day 29  
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           _____________________________________________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_________________________________________________________________ _________________________________________________________________________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 29                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx .x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defined as the pre -dose body weight  value on Day 1 . 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 34 of 100 Table 14.2. 8 ANCOVA Results on Mean Change in Body Weight  from Baseline  to Day 29   
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_________________________________________________________ _________________________________________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
_____________________________________________________________________________________________________________________________ ____________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the pre -dose body weight  value on Day 1 . 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 35 of 100 Table 14.2. 9 Descriptive Summary of Change in HbA1c  from Baseline  to Day 29   
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           _____________________________________________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_____________________________________________________________________________________ _____________________________________________________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 29                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx   xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , x x     xx , xx           xx , xx           
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defi ned as the pre -dose HbA1c value on Day 1 . 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 36 of 100 Table 14.2. 10 ANCOVA Results on Mean Change in HbA1c  from Baseline  to Day 29  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidenc e  P-value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_________________________________________________________________________________________ _________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Pla cebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
________________________________________________________________________________________________________________ _________________________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are fr om two-sided test  
                 at 5%-level. 
Note: Baseline is defined as the pre -dose HbA1c value on Day 1 . 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 37 of 100 Table 14.2. 11 Descriptive Summary of Change in 24 h UGE  from Baseline to Day 28  
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           ____________________________________ _________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_____________________________________________________________________________________________________________________________ _____________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 1                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
 
Day 28                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                    
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
to Day 1     Mean ± SD        xx.x ± x. xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
 
Change from baseline            n                xx               xx               xx     xx                xx                                                          
to Day 28     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                   
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defined as the 24h UGE on Day 0. 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 38 of 100 Table 14.2. 12 ANCOVA Results on Mean Change in 24 h UGE  from Baseline  to Day 28   
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
____________________________________________________________________________ ______________________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT00 [ZIP_CODE] vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
____________________________________________________________________________________________________________ _____________________________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans    
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent  variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the 24h UGE on Day 0. 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:m m)                                    
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 39 of 100 Table 14.2.1 3 Summary of Plasma  Concentrations of EGT0001442  (ng/mL )  
 Dose Escalation Seg ment  
 
________________________________________________________________________________________________________________ _______________  
   
Dose        Subject  0 0.5 1 2 3  4 6 8 10 12 24  48  
Group    Center    Number  hr hr hr hr hr hr hr hr hr  hr hr hr  
________________________________________________________________________________________________________________ _______________  
5 mg EGT0001442    01     01  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx 
       02  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx  
       03  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx  
 
     ... 
 
 
   
 
       N          xx xx xx xx xx xx xx xx xx xx xx xx 
       MEAN       xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx 
       SD         xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       CV%        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MEDIAN     xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MIN        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MAX        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx 
_________________________________________________________________________________________________________________ ______________  
 
Note: table will continue for 10mg, 20mg and 50mg dose groups.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617385] AUC0-t    AUC0-24  AUC0-inf  Cmax   Tmax  Thalf Kel  Vz/F  CL/F  AUC0-t   AUC0-24  AUC0-inf  Cmax    
Group           Number (ng.h/mL)  (ng.h/mL)  (ng.h/mL) (ng/mL) (h)   (h)   (1/h)  (L)  (L/h) (ng.h/mL)(ng.h/mL) (ng.h/mL)  (ng/mL)      
________________________________________________________________________________________________________________ _______________  
5 mg EGT0001442   01    xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    02  xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x      
   
      ... 
 
 
   
 
    N        xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MEAN     xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    SD       xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    CV%      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MEDIAN   xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MIN      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MAX      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    GM*  xxxx.x    xxxx.x    xxxx.x    xxx.x    
________________________________________________________________________________________________________________ _______________  
Note: *GM = Geometric Mean  
 
Note: table will continue for 10mg, 20mg and 50mg dose groups.  
 
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617386] Prandial Blood Glucose (mg/dL)  in Change from Day 0 to Day 2   
Dose Escalation Segment                          
_______________________________________________________________________ _____________________________________ _____________________  
                 Dose Group  
                         ________________________________________________ _________________________              
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
          5 mg           10 mg          20 mg          50 mg                  
Day   Meal  Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)          
____________________________________________________________________________________________________________ _____________________  
Day [ADDRESS_617387]  n                xx               xx               xx     xx                   
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
Day [ADDRESS_617388]  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x .xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                   
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
Change from Day [ADDRESS_617389]  n                xx               xx               xx     xx                  
to Day     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                   
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
_______________________________________________ _____________________________________________________________________________ _____ 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617390] Prandial Blood Glucose in AUC (mg.h/dL ) 
Dose Escalation Segment        
                    
____________________________________________________________________________________________________________ __________________________  
                  
           Dose Group  
                         __________________________________________________ ___________________________             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
          5 mg           10 mg          20 mg          50 mg                  
Day     Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)          
____________________________________________________________________________________________________________ __________ ________________  
 
Day 0            n                xx               xx               xx     xx                   
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
 
Day 2            n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       
Change from Day 0 to Day 2        n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
  
     
___________________________________________________________________________________________________________ ___________________________  
(Source: path \program na me  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
      
      
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 43 of 100 Table 14.3.1 .1 Summary of T EAEs  
Double -blind Segment  
 Double -blind Safety Analysis Set  
             
_______________________________________________________________________________________________________ ________________________  
  
                                                   Treatment Group   
         _________________________________________________ _________________________ _________________  
 
          EGT0001442         EGT0001442           EGT0001442         EGT0001442                    
                                      Placebo             5 mg               10 mg           20 mg              50 mg                   
                               (N=xx)             (N=xx)             (N=xx)               (N=xx)              (N=xx) 
________________________________________________________________________________________________________ ___________ ____________                     
All TEAEs       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                           
Deaths       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                          
Serious TEAEs       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                           
TEAEs leading to withdrawal     xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                         
TEAEs related to study drug     xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                            
   
______________________________________________________________________________________________________ _________________________  
N:  Number of subjects exposed in specified group                      
%:  Percentage based on N  
E:  Number of TEAEs  
 
 
 (Source: path\program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 44 of 100 Table [IP_ADDRESS] Summary of T EAEs   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
             
_______________________________________________________________________________________________________ ________________________  
  
                                                   Dose Group  
         ______________________________________________________ _____________________________________  
 
           EGT0001442         EGT00014 42           EGT0001442        EGT0001442                    
                                       5 mg           10 mg           20 mg           50 mg                  
                                (N=xx)             (N=xx)               (N=xx)            (N=xx)               
_______________________________________________________________________________________________________ ________________________                      
All TEAEs        xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                               
Deaths         xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                            
Serious TEAEs         xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E      
TEAEs leading to study disc ontinuation xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                                                       
TEAEs related to study drug       xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                               
   
______________________________________________________________________________________________________ _________________________  
N:  Number of subjects exposed in s pecified group                     
%:  Percentage based on N  
E:  Number of TEAEs  
 
 
Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 45 of 100 Table 14.3. 1.3 Summary of TEAEs  by [CONTACT_1196], Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
    
___________________________________________________________________________________________________________________ ___________________  
 
                                                   Treatment Group   
               ___________________________________________________________ __________________________  
             
              EGT0001442         EGT0001442        EGT0001442         EGT0001442                    
System Organ Class                         Placebo             5 mg           10 mg            20 mg        50 mg                   
   Preferred Term                        (N=xx)              (N=xx)             (N=xx)             (N=xx)             (N=xx)                                         
____________________________________________________________________________________________________________________ ____________ ______                     
 
Subject with at least one AE    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
   PT1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 PT2     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
   PTxx      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 2     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
   PT1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 PT2     xx ( xx.x%)         xx ( xx.x%)        xx ( x x.x%)        xx ( xx.x%)        xx ( xx.x%)  
   PTxx      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
SOC 3       
 
____________________________________________________________________________________________________________________ __________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ clas s/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specifi ed group  
      %: Percentage based on N  
 
Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 46 of 100  
Similar tables:  
 
Table 14.3. 1.4 Summary of Drug -related TEAEs  by [CONTACT_1196], Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.5 Summary of TEAEs Leading to Study Discontinuation  by [CONTACT_1196], Preferred Term and Treatment 
Group  
Double -blind Segment   
 Double -blind Safet y Analysis Set  
 
Table 14.3. 1.6 Summary of Serious TEAEs  by [CONTACT_1196], Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 47 of 100 Table 14.3. 1.7 Summary of T EAEs  by [CONTACT_1196], Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
    
___________________________________________________________________________________________________________________ ________________________  
                                                     
                  Dose Group  
                  ___________________________________________________________ ___________________  
              
       EGT0001442           EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                               5 mg        10 mg  20 mg            50 mg                  
   Preferred Term                               (N=xx)               (N=xx)             (N=xx)             (N=xx)              
___________________________________________________________________________________________________________________ ________________________                        
 
Subject with at least one AE      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx  ( xx.x%)         
 
SOC 1       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PT1       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 PT2       xx ( xx.x%)         xx ( xx.x%)        xx ( x x.x%)        xx ( xx.x%)         
   PTxx        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
SOC 2       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PT1       xx ( xx.x%)         xx ( x x.x%)        xx ( xx.x%)        xx ( xx.x%)         
 PT2       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PTxx        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
            xx ( xx.x %)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
SOC 3       
 
_________________________________________________________________________________________________________________ __________________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once  (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 48 of 100 Similar  tables:  
 
Table 14.3. 1.8 Summary of Drug -related TEAEs by [CONTACT_1196], Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
Table 14.3. 1.9 Summary of TEAEs Leading to Study Discontinuation by [CONTACT_1196], Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
Table 14.3. 1.10 Summary of Serious TEAEs by [CONTACT_1196], Preferred Term and Dose  Group 
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 49 of 100 Table 14.3. 1.11 Summary of TEAEs  by [CONTACT_480362] -blind Segment   
 Double -blind Safety Analysis Set  
 
___________________________________________________________________________________________________________________ ________________________  
 
                                                    Treatment Group   
                       _______________________ ____________________________________________________________________  
             
               EGT0001442         EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                                Placebo             5 mg  10 mg     20 mg        50 mg                   
   Preferred Term          Severity         (N=xx)              (N=xx)             (N=xx)             (N=xx)             (N=xx)                                             
____________________________________________________________________________________________________________________ _______________________                       
Subject with at least one AE  Mild    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x %) 
 
SOC 1    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx  ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
  
  PT1    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
  PTxx    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 2    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
____________________________________________________________________________________________________________________ _______________________  
Note: Counts reflect num bers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 50 of 100 Table 14.3. 1.12 Summary of T EAEs  by [CONTACT_480363]  
 
___________________________________________________________________________________________________________________ ________________________  
 
                                                    Treatment Group                                           
                                            ___________________________________________________________________________________________  
             
         EGT0001442          EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                                  5 mg               10 mg         20 mg            50 mg                  
   Preferred Term           Severity         (N=xx)              (N=xx)             (N=xx)             (N=xx)                                                         
__________________________________________________________________________________________________________________ _________________________                         
Subject with at least one AE   Mild    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)           
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
SOC 1     Mild     xx ( xx.x%)         x x ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
         
  PT1     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
        
  PTxx     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
 
SOC 2     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)           
____________________________________________________________________________________________________________________ _______________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 51 of 100 Table 14.3. 1.13 Clinical Laboratory Evaluations in Biochemistry  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
_____________________________________________________________________________________________________________________________ ______________  
                                          
           Treatment Group   
                    ___________________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                           
_____________________________________________________________________ _______________________________________ _______________________________  
 
Albumin (G/L)     Screening  n                xx               xx               xx     xx                xx       
(30 - 50)                  Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                         ... 
         
  
ALT(SGPT)  (U/L)      Screening   n                xx               xx               xx     xx                xx                                                          
(8 – 54)    Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          x x , xx          xx , xx     xx , xx           xx , xx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue fo r other visit day s 2, 8, 15, 22, 29, 35 and 43  and will continue for other lab parameters.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 52 of 100  
Table 14.3. 1.14 Clinical Laboratory Evaluations in Change from Baseline in Biochemistry  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
__________________________________________________________________________________________________ __________ _______________________________  
                                          
           Treatment Group   
                    ___________________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                           
_____________________________________________________________________________________________________________________________ ______________  
 
Albumin (G/L)      Day 2 n                xx               xx               xx     xx                xx       
(30 - 50)                        Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
        Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
ALT(SGPT)  (U/L)        Day 2     n                xx               xx               xx     xx                xx  
(8 – 54)                         Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
______________________________________ _____________________________________________________________________ _______________________________  
Note: Baseline is defined as the last observed measurement prior to dosing  on Day 1 at Visit 5 . 
Note: *P -values are from paired t -test. 
Note: Table will co ntinue for other visit days 15, 22, 29, 35 and 43  and will continue for other lab parameters.  
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 53 of 100 Table 14.3. 1.15 Biochemistry Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
      
_______________________________________________________________________________________________________ ____________________________  
 
                                                                                  Day 1 / Baseline                 
                                                    ________________________________________________ ___________________________  
                                                                          
Lab                           Visit       Missing      Below LLNR    Normal      Above ULNR      Total      
Parameter        Treatment       Day       n (%)        n (%)         n (%)       n (%)           n (%)    
_______________________________________________________________________________________________ ____________________________________  
                                                                                        
Albumin ( G/L)    Placebo (N=xx) Day 2  Missing           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
(30 - 50)                                 Below LLNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Normal            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Above ULNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Total             xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx (100.0)  
                                                                                                      
                 Day 8  Missing           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Below LLNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                              Normal            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Above ULNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Total             xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx (100.0)  
     ... 
 
       EGT0001442 5 mg (N=xx)    
 
... 
 
____________________________________________________ _____________________________________________________________________________ _ 
Note:  N: Number of subjects in the specified group  
     n: Number subjects with data available  
       %: Percentage based on N  
    LLNR: Lower Limit of Normal Range  
    ULNR: Upper Limit of Normal Range      
 
Table will continue for other visit days 15, 22, 29, 35 and 43  and for other treatment group and other lab parameters.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 54 of 100  
Similar  tables:      
Table 14.3. 1.16 Clinical Laboratory Evaluations in Hematology  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.17 Clinical Laboratory Evaluations in Change from Baseline in Hematology  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.18 Hematology  Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.19 Clinical Laboratory Evaluations in Urinalysis (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.20 Clinical Laboratory Evaluations in Change from Baseline in Urinalysis  
Double -blind Segment   
 Double -blind Safety Anal ysis Set  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 55 of 100 Table 14.3. 1.21 Urinalysis Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
      
_______________________________________________________________________________________________________ __________________________  
 
                                                                             Day 1 / Baseline  
                                                    ________________________________ _______________________________   
                                                                          
Lab                           Visit       Missing      Normal       Abnormal     Total      
Parameter        Treatment       Day       n (%)        n (%)        n (%)        n (%)              
___________________________________________________________________________________________________ ______________________________  
                                                                                        
Albumin ( G/L)    Placebo (N=xx)   Day 2   Missing          xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
(30 - 50)                                 Normal           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Abnormal         xx ( xx.x )   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Total            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx (100.0)  
                                                                                                     
     Day 8   Missing          xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                               Normal           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Abnormal         xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Total            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx (100.0)  
     ... 
 
       EGT0001442 5 mg (N=xx)    
 
... 
 
_____________________________________________________________________________________________________ ____________________________  
Note:  N: Number of subjects in the specified group  
     n: Number subjects with data available  
       %: Percentage based on N 
    
 
Table will continue for other visit days 15, 22, 29, 35 and 43  and for other treatment group and other lab parameters.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 56 of 100 Table 14.3. 1.22 Clinical Laboratory Evaluations in Biochemistry (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
                 Dose Group  
                       __________________________________________ _________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit      5 mg           10 mg   20 mg           50 mg                  
      Day   Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Albumin (G/L)     Screening   n                xx               xx               xx     xx   
(30 - 50)                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.x x   xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                         ... 
         
  
ALT(SGPT)  (U/L)     Screening      n                xx               xx               xx     xx  
(8 – 54)                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                              Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                                      
... 
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other visit days 2, 3, 8, 15, 22, 23 and 43  and will continue for other lab parameter s. 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 57 of 100                                 
 
 
Similar tables:  
 
 
Table 14.3. 1.23 Clinical Laboratory Evaluations in Hematology  (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
 
Table 14.3. 1.24 Clinical Laboratory Evaluations in Urinalysis  (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 58 of 100  
Table 14.3. 1.25 Summary of Vital Signs  (Observed Values)  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           _______________________________________________________________________________  
                
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
       Day   Statistic       (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
____________________________________________________________________________________________________________ _______________________________  
 
Pulse (beats/minute)  Screening   n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2            n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              x x.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1/Pre-dose     n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
      Day 2/Pre-dose 
      Day 8   
      Day 15   
                     Day 22   
                     Day 29   
                     Day 35 
      Day 43                
  
Systolic BP (mmHg)   Screening   n               xx               xx               xx     xx                xx                                                          
      Mean ± SD       xx.x ± x .xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x                                         
      Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                                            
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue for other vital signs . 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)   
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 59 of 100 Table 14.3. 1.26 Summary of Vital Signs in Change from Baseline  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           ___________ _____________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
___________________________________________________________________________________________________________ ______________ __________________  
 
Pulse (beats/minute)  Day 2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx 
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
        Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
Systolic BP (mmHg)    Day 2      n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Baseline is defined as the l ast observed measurement prior to dosing on Day 1 at Visit 5. 
Note: *P -values are from paired t -test. 
Note: Table will continue for other days 8, 15, 22, 29, 35 and 43 an d will continue for other  vital signs.  
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
                                                               
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 60 of 100  
Table 14.3. 1.27 Summary of Vital Signs (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
                 Dose Group   
                          _____________________________________________________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit     5 mg           10 mg          20 mg           50 mg                  
      Day  Statistic           (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Pulse (beats/minute)  Screening   n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/Pre -dose     n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/1 hr          
       Day 1/2 hr         
       Day 1/4 hr     
                      Day 1/8 hr          
       Day 2/Pre-dose                
                      Day 3/Pre-dose      
       Day 8              
                      Day 15    
                      Day 22 
                      Day 29 
                      Day 43         
  
Systolic BP (mmHg)      
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other vital signs  
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 61 of 100 Table 14.3. 1.28 Summary of 12-Lead ECG  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
__________________ __________________________________________________________________________________________ _______________________________  
                                      
           Treatment Group   
                           __________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit     Placebo   5 mg  10 mg     20 mg       50 mg                  
       Day   Statistic        (N=xx)         (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
_________________________________________________________________________________________________ ___________ _______________________________  
 
PR Interval (ms)      Screening   n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2  n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1/Pre-dose n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
       Day 2/Pre -dose 
                      Day 29         
  
QRS Interval (ms)     Screening      n               xx               xx               xx     xx                xx                                                          
      Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x  ± x.xx   xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                              Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue for other ECGs. 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)   
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 62 of 100 Table 14.3. 1.29 Summary of 12 -Lead ECG in Change from Baseline  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           ___________________ ________________________________________________________________  
                   
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
       Day       Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
______________________________________________________________________________________________________ _____________________________________  
 
PR Interval (ms)      Day 2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
       Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
QRS Interval (ms)      Day 2     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Baseline is d efined as the last observed measurement prior to dosing on Day 1 at Visit 5. 
Note: *P -values are from paired t -test. 
Note: Table will continue for other days 15, 22 and 29 and will continue for other ECGs.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddm mmyyyy:hh:mm)                                                                 
 
 
                                                                                                                           
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 63 of 100 Table 14.3. 1.30 Summary of 12-Lead ECG (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                                                
____________________________________________________________________________________________________________ ____________ ___________  
                                          
                 Dose Group   
                      _______________________________________________ __________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit     5 mg           10 mg          20 mg           50 mg                  
      Day   Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Pulse (beats/minute)  Screening   n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/Pre -dose n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/2 hr 
                      Day 2/Pre -dose 
                      Day 29         
  
Systolic BP (mmHg)    Screening   n                xx               xx               xx     xx                                                                        
      Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                              Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                                      
... 
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other ECGs. 
 
(Source: path \program name  [CONTACT_1782]/t ime of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 64 of 100 Table 14.3. 1.31 Summary of Fasting Plasma Glucose  by [CONTACT_4838]  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
          Treatment Group   
             ___________________________________________________________________________________ _____ 
             
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
Visit      Placebo    5 mg       10 mg      20 mg           50 mg                  
Day  Statistic          (N=xx)           (N=xx)           (N=xx)            (N=xx)            (N=xx)                                            
__________________________________________________________________________________ __________________________ _______________________  
 
Screening   n                xx               xx               xx    xx                xx                                                           
         Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx      xx , xx           xx , xx  
  
Day -2  n                xx               xx               xx      xx                xx                                                           
   Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx        xx , xx           xx , xx  
 
Day 1  n                xx               xx               xx      xx                xx                                                           
   Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx     xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx      xx , xx           xx , xx           
... 
         
  
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for Days 2,8,15,22, 27,29,35,41 and 43. 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 65 of 100 Table 14.3. 1.32 Summary of Concomitant Medication  
Double -blind Segment   
 Double -blind Safety Analysis Set  
             
_______________________________________________________________________________________________________ ______________________  
  
                                           Treatment  Group  
     ______________________________________________________________________ _______________ __ 
 
       EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
     Placebo  5 mg           10 mg            20 mg      50 mg                  
Preferred Medication Term   (N=xx)         (N=xx)           (N=xx)           (N=xx)    (N=xx)                             
_________________________________________________________________________________________ _____________ _______________________                       
Any Medication      xx ( xx.x%) xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x %)  xx ( xx.x%)     
            
ConMed 1       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 2       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 3       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 4       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
     
  
 
______________________________________________________________________________________________________ _______________________  
Note: A subject is counted only once per concomitant medication.  
N: Number of subjects exposed                     
%: Percentage is based N 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 66 of 100  
Table 14.3. 1.33 Summary of Concomitant Medication  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
             
________ _______________________________________________________________________________________________ ______________________  
  
                                         Dose Group  
        ______________________________________ ____________________________  
 
     EGT0001442      EGT0001442       EGT0001442      EGT0001442                    
     5 mg         10 mg            20 mg           50 mg                  
Preferred Medication Term   (N=xx)         (N=xx)           (N=xx)          (N=xx)                                      
________________________________________________________________________________________________________ _____________________                     
Any Medication      xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)       
            
ConMed 1      xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 2       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 3       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 4       xx ( xx.x%)  xx ( xx.x%)        xx ( xx.x%)    xx ( xx.x%)    
     
  
 
______________________________________________________________________________________________________ _______________________  
Note: A subject is counted only once per concomitant medication.  
N: Number of subjects in the specified group  
%: Percentage is based N 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
Theracos, Inc. Protocol No. THR -[ADDRESS_617391]/       Termination            Termination                     
Segment  Treatment         Center  Number  Contact        [CONTACT_480364]         
______________________________________________________________________________________________________ __________ ___________________  
Double-blind Placebo       02 [ZIP_CODE]    ddmmmyyyy      Completed  
           [ZIP_CODE]    ddmmmyyyy      Discontinued due to adverse event  xxxxxxxxxxxxxxxxxxxx  
               ... 
                  ...                               
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg       01  003     ddmmmyyyy      Completed  
               ...  
      ... 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
 
 
________________________________________________________________________________________________________________ ___________________  
 
 
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617392] Deviation        Deviation  Description of        Deviation  
Segment          Treatment      Center Number   Date /Time  Page ID      Category  Deviation    Major/minor  
________________________________________________________________________________________________________________ _______________  
Double-blind      Placebo        02    [ZIP_CODE]   ddmmmyyyy/hhmm  EX0012      DOSING xxxxxxxxxxxxx           Minor 
       ... 
      ... 
 
 
       EGT0001442 5 mg 
 
               EGT0001442 10 mg 
 
               EGT0001442 20 mg 
 
               EGT0001442 50 mg 
 
                   
Dose Escalation   EGT0001442 5 mg    01  003   ddmmmyyyy/hhmm  EX0012      DOSING xxxxxxxxxxxxxx    NA    
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
         
               
 
________________________________________________________________________________________________________________ ______________  
 
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617393] s Excluded from the Efficacy Analysis  (Double -blind Segment ) 
 
_____________________________________________________________________________________________________________ ________________  
  
     Subject                 
Treatment   Center  Number      Safety Population  ITT Population   PP Population  
____________________ _________________________________________________________________________________________ ________________  
Placebo  02  [ZIP_CODE]     Yes   No  No 
               
 
 
 
 
EGT0001442 5 mg 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
 
 
_____________________________________________________________________________________________________________ ________________  
 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)      
 
                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 71 of 100 Listing [IP_ADDRESS] Demographics  
 
_____________________________________________________________________________________________________________ ________________________  
  
Study     Subject    Date of    Age        Height    Weight   BMI   
Segment  Treatment    Center Number     Birth   (yrs)   G ender   Race   Ethnicity    (cm)      (kg)    (kg/m^2)     
__________________________________________________________________________________________ ______________ _____________________________  
Double-blind      Placebo      02  [ZIP_CODE]    ddmmmyyyy    xx      Male    White  Hispanic  or Latino   xxx    xxx.x     xxx.x 
               
                     ... 
 
                              ... 
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
_____________________________________________________________________________________________________________ ______________________ _ 
 
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617394]  Seq.  Body                 Medical history      Start                 Stop     
Segment          Treatment   Center   Number   No.   System            Findings       Date     Ongoing     Date    
________________________________________________________________________________________________________________ ___________________  
Double-blind     Placebo      02      [ZIP_CODE]     1    Eyes, Ears, Nose, Throat   NORMAL 
            2    Neurologica l           OCCASIONAL HEADACHES UNKUNK1989    Yes 
            3    Cardiovascular           HIGH CHOLESTEROL     UNKUNK2007    Yes 
            4    Skin            BALANITIS      21DEC2009      29DEC2009  
      
       ...   
                                       ...            
       ... 
    
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
  
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ __________________  
 
(Source: path \program name  [CONTACT_1782] /time of run: ddmmmyyyy:hh:mm)   
 
 
 
                                                               
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617395]    WHO Drug Name     [CONTACT_480367]/Stop          Drug             Frequency  Route of          
Segment        Treatment  Center Number       Medication Name   [CONTACT_480368]     
_____________________________________________________________________________________________________________________________ __________ __ 
               
Double-blind      Placebo   02      [ZIP_CODE]   xxxxxxxx xxxxxxxxxx    ddmmmyyyy/  No      xx        mg     bid       PO           xxxxxxxxx      
           xxxxxxxxxxxxxxxxx     ddmmmyyy  
                                               xxxxxxxxxxxxxx  
     ... 
 
 
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
__________________________________________________________________________________________________________ _______________________________  
 
 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
                                                                                
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 74 of 100 Listing 16.2.4. 4 Inclusion/Exclusion Criteria and Exceptions  
 
________________________________________________________________________________________________________________ ___________________  
 
          Were all                        
          Inclusion/               Inclusion/Exclusion      Was a  Date 
Study                   Subject  Exclusion      Consent    Washout    ___________________       Waiver  of Waiver  
Segment       Treatment  Center  Number  Criteria met?    Date Type*      Category        No.      Granted?  Granted 
________________________________________________________________________________________________________________ ___________________  
 
Double-blind     Placebo    02    [ZIP_CODE]       Yes     ddmmmyyyy   1 
                          [ZIP_CODE]       No     ddmmmyyyy   2           Includion     2        Yes  ddmmmyyyy  
   
      
 
 
      
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
________________________________________________________________________________________________________________ ___________________  
Note: *Washout Type: 1 = Diabetic Med  Discontin ued, 2 = Diabetic Med Naïve   
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
 
 
 
                                            
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617396]              
Segment       Treatment   Center    Number     Day    Date/Time         Name     [CONTACT_480369] 
________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo      02  [ZIP_CODE]  Screening ddmmmyyyy /hhmm   Amphetamines    Negative          
                Barbiturates    Negative  
                Cocaine metabolites   Negative  
                Opi[INVESTIGATOR_480347] 0    ddmmmyyyy/hhmm     Amphetamines    Negative   
                Barbiturates    Negative  
                Cocaine metabolites   Negative  
                Opi[INVESTIGATOR_480348]  
                                ... 
      
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
________________________________________________________________________________________________________________ _____________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617397]  Dose 10 hours   Dose     Dose         
Segment  Treatment    Center  Number   Day Prior to dose?   Date/Time   Status   
________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo      02 [ZIP_CODE]         1   Yes   ddmmmyyyy /hhmm  Dosed 
        2   Yes   ddmmmyyyy/hhmm   Dosed 
        3   Yes   ddmmmyyyy/hhmm   Dosed 
        4      ddmmmyyyy/hhmm   Dosed 
        5      ddmmmyyyy/hhmm   Dosed 
        6      ddmmmyyyy/hhmm   Dosed 
        7      ddmmmyyyy/hhmm   Dosed 
                                    ... 
  
        27      ddmmmyyyy/hhmm   Dosed 
        28      ddmmmyyyy/hhmm   Dosed 
       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                  
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 77 of 100  
Listing [IP_ADDRESS] Fasting Plasma Glucose (mg/dL )  
                                                                     
______________________________________________________________________________________________________________ _______________  
                                                                 
                                                                          Observed FPG                           
Study                  Subject   Visit   Test        Results          
Segment   Treatment         Center  Number   Day         Repeat  Date/Time         (mg/dL)           
________________________________________________________________________________________________________________ _____________  
Double-blind     Placebo            02 [ZIP_CODE]  Screening    ddmmmyyyy/ hh:mm     xxxx.x 
         Day -2   ddmmmyyyy/ hh:mm     xxxx.x 
         Day 1           ddmmmyyyy/ hh:mm     xxxx.x        
         Day 2           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 8           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 15           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 22          ddmmmyyyy/ hh:mm     xxxx.x     
         Day 29    ddmmmyyyy/ hh:mm     xxxx.x     
         Day 35    ddmmmyyyy/ hh:mm     xxxx.x 
         Day 43    ddmmmyyyy/ hh:mm     xxxx.x      
   ... 
       
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg    01    003      Screening    ddmmmyyyy/hh:mm     xxxx.x 
         Day 0   ddmmmyyyy/hh:mm     xxxx.x 
         Day 1     ddmmmyyyy/hh:mm     xxxx.x     
         Day 2     ddmmmyyyy/hh:mm     xxxx.x     
         Day 3          ddmmmyyyy/hh:mm     xxxx.x     
         Day 8           ddmmmyyyy/hh:mm     xxxx.x    
         Day 15           ddmmmyyyy/hh:mm     xxxx.x    
         Day 22           ddmmmyyyy/hh:mm     xxxx.x     
         Day 29          ddmmmyyyy/hh:mm     xxxx.x     
         Day 43   ddmmmyyyy/hh:mm     xxxx.x      
                  
   ...                                     
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                  
 
                                                                    
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 78 of 100  
Listing [IP_ADDRESS]  Weight  
 
__________________________________________________________________________________________________________ ___________________  
                          
Study       Subject        Visit     Visit  Weight         
Segment  Treatment    Center Number    Day       Date    (kg)          
__________________________________________________________________________________________________________ ___________________  
 
Double-blind      Placebo        02 [ZIP_CODE]       Screening          ddmmmyyyy   xx.x            
          Day -2     ddmmmyyyy   xx.x    
          Day 1   ddmmmyyyy   xx.x    
         Day 8       ddmmmyyyy  xx.x    
          Day 15     ddmmmyyyy  xx.x    
          Day 22     ddmmmyyyy  xx.x    
          Day 29     ddmmmyyyy  xx.x    
          Day 35     ddmmmyyyy  xx.x  
         Day 43     ddmmmyyyy  xx.x   
                ... 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg      01 003      Screening         ddmmmyyyy   xx.x           
          Day 0      ddmmmyyyy   xx.x    
          Day 1   ddmmmyyyy   xx.x    
         Day 3       ddmmmyyyy  xx.x    
          Day 15     ddmmmyyyy  xx.x    
          Day 22     ddmmmyyyy  xx.x    
          Day 29     ddmmmyyyy  xx.x    
          Day 43     ddmmmyyyy  xx.x    
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
 
___________________________________________________________________________________________________________ __________________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
                                                                         
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 79 of 100 Listing 16.2.6. 3 Glycated Hemoglobin A 1 (HbA1c)  (%)  
                                                                     
________________________________________________________ ________________________________________________________ ______________  
                                                                       
                                                                            Observed HbA1c                       
Study          Subject   Visit                    Test       Results        
Segment  Treatment       Center  Number      Day      Repeat  Date/Time         (%)    
________________________________________________________________________________________________________________ ______________  
Double-blind     Placebo          02 [ZIP_CODE]      Screening        ddmmmyyyy/hh:mm     xx.x 
         Day 1   ddmmmyyyy/hh:mm     xx.x        
         Day 29           ddmmmyyyy/hh:mm     xx.x      
        
             
 
          
   ...       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ _______________  
  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyy yy:hh:mm)                                  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 80 of 100 Listing [IP_ADDRESS] 24 h UGE ( g/day) 
                                                                     
________________________________________________________________________________________________________________ ___________________  
                                                                       
                                                                           Observed UGE                      
Study              Subject   Visit   Test             Results         
Segment   Treatment       Center     Number     Day        Repeat  Date/Time            (g/day)           
________________________________________________________________________________________________________________ ___________________  
Double-blind     Placebo          02    [ZIP_CODE] Screening       ddmmmyyyy/hh:mm     xxxx.x 
         Day 1   ddmmmyyyy/hh:mm     xxxx.x       
         Day 29           ddmmmyyyy/hh:mm     xxxx.x     
        
             
 
          
   ...       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ____________________  
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 81 of 100  
Listing 16.2. 6.5 Blood (PK) Sample Collection  (Dose Escalation Segment)  
                                                                                                                                          
_________________________________________________________________________________________________________ ______________________  
                                                                                                     
          Subject  Sample      Study         Scheduled      Scheduled     Actual      Reason for              
Treatment          Center Number   Number      Hour          Date            Time          Time        Deviation               
_________________________________________________________________________________________________________ ______________________  
                                                                                                                                          
EGT0001442 5 mg     01      003   1      PRE-DOSE 10Dec2009                 0619  
       2     0.5 H  10Dec2009                 0830  
       3     1 H  10Dec2009                 hhmm  
       4     2 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       5     3 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       6     4 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       7     6 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       8     8 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       9     10 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       10     12 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       11     24 H  10Dec2009                 hhmm  
       12     48 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                  
 
 
 
 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ _______________  
Note: Scheduled time is only entered if differ from actual time.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 82 of 100  
Listing [IP_ADDRESS] Post Prandial Blood Glucose (mg/dL ) (Dose Escalation  Segment)  
                                                                     
________________________________________________________________________________________________________________ ___________________  
                      Change from                                                                       
                                                                         Observed   Pre-meal to                     
                Subject Visit  Time                      Test          Results   Post-meal     AUC 
Treatment         Center Number  Day    Point              Date/Time         Name        (mg/dL)   (mg/dL)      (mg.h/dL)  
________________________________________________________________________________________________________________ ___________________  
EGT0001442 [ADDRESS_617398]  09Dec2009/[ADDRESS_617399]  09Dec2009/ 1107    BLOOD GLUCOSE  291  71 
       Prior to Lunch   09Dec2009/ [ADDRESS_617400] Lunch  09Dec2009/ 1517    BLOOD GLUCOSE  243  67 
       Prior to Dinner 09Dec2009/ [ADDRESS_617401] Dinner  09Dec2009/ 2018    BLOOD GLUCOSE  241  57 
       10:00 PM   09Dec2009/ [ADDRESS_617402]  11Dec2009/[ADDRESS_617403]  11Dec2009/1107    BLOOD GLUCOSE  272  52 
      Prior to Lunch   11Dec2009/[ADDRESS_617404] Lunch  11Dec2009/1517    BLOOD GLUCOSE  243  67 
      Prior to Dinner  11Dec2009/[ADDRESS_617405] Dinner  11Dec2009/2018    BLOOD GLUCOSE  243  59 
      10:00 PM   11Dec2009/2245    BLOOD GLUCOSE  220                xxxx.x   
          
   ... 
       
                                 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ____________________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 83 of 100 Listing [IP_ADDRESS] Treatment Emergent Adverse Events  
 
_______________________________________________________________________________________________________________ _______________________  
                                                                                                                                                                                                                          
                                            System Organ Class                                        Relationship                                
Study                    Subject  AE    Preferred Term    Onset/Resolution                to       Action              
Segment     Treatment  Center Number   No.     Verbatim Term    Date     Time   Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ _______________________  
                                                                                                                                                                                                                             
Double-blind  Placebo     02    [ZIP_CODE]  1     xxxxxxxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx     ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________________  
                                                                     
Note: * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate , 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1  = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospi[INVESTIGATOR_059], 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing w ithout Treatment, 10 = Death.                        
  
Sorting by: [CONTACT_480365], Treatment, Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 84 of 100  
Similar Listings:                                                                 
 
 
Listing 16.2.[ADDRESS_617406]  AE    Preferred Term    Onset/ Resolution                             to       Action              
Segment         Center    Number   No.     Verbatim Term   Date     Time    Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ _____________ _______ 
                                                                                                                                                                                                                             
Double-blind      02       [ZIP_CODE]     1     xxxxxxxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx    ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
 
    
    
    
    
 
Dose Escalation    
    
   
 
_______________________________________________________________________________________________________________ ____________________  
                                                                     
Note:  
    * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate, 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1 = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospi[INVESTIGATOR_059], 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing without Treatment, 10 = Death.                        
  
Sorting by: [CONTACT_480365], Washout type , Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617407]  AE    Preferred Term    Onset/ Resolution                to       Action              
Segment       Type+  Center Number   No.     Verbatim Term   Date     Time    Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ ________________________  
                                                                                                                                                                                                                             
Double-blind     1      02    [ZIP_CODE]    1     xxxxx xxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx     ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
   
 
Dose Escalation    
 
_______________________________________________________________________________________________________________ ________________________  
                                                                     
Note: + Washout type: 1=  Diabetic Med Discontinued , 2= Diabetic Med Naive 
    * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate, 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1 = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospi[INVESTIGATOR_059], 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing without Treatment, 10 = Death.                        
  
Sorting by: [CONTACT_480365], Washout type , Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617408] Age/   Visit        --------------   Lab     Test         Normal    
Segment       Treatment   Center  Number  Gender Day  Repeat  Date    Time    Test    Results Unit Range     Flag *  Comments  
________________________________________________________________________________________________________________ _______________________  
Double-blind     Placebo     02     [ZIP_CODE]   36/M    Screening    ddmmmyyyy hh:mm  Albumin   xx    xx   xx-xx   L(NCS)   xxxxxxxxx  
                                                Calcium    xx    xx   xx-xx    
                                                                                     Creatinine xx    xx   xx-xx    
             
                                                                                       ... 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ _______________________  
 
 Note: * Flag: L = Low, H = High , NCS = Not clinical significance, CS = Clinical significance  
 
Table will continue for other biochemistry lab tests.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 88 of 100 Similar listings:  
 
Listing 16.2. 8.[ADDRESS_617409]  Visit         Seated for    Rate      BP         BP    Rate         Temperature  
Segment        Treatment  Center  Number   Day         5 minutes?   (BPM)     (mmHg)     (mmHg)     (breaths/min)  (ºC)   
_____________________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo     02    [ZIP_CODE]   Screening           Yes        xxx        xxx   xxx      xx.x          xx.x  
        Day -2              Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 1/Pre-dose      Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 2/Pre-dose      Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 8           Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 15        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 22        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 29        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 35        Yes        xxx        xxx   xxx      xx.x   xx.x 
       Day 43        Yes        xxx        xxx   xxx      xx.x   xx.x 
 
             ...   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  01  003   Screening          Yes         xxx        xxx   xxx      xx.x          xx.x 
                     Day 0           Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/Pre -dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/1 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/2 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/4 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/8 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 2/Pre-dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 3/Pre-dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 8           Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 15       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 22       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 29       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 43         Yes         xxx        xxx   xxx      xx.x          xx.x 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
_____________________________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
                                                                         
  
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617410] Visit      Rate   Interval Interval  Interval Interval Findings     Repeat ECG 
Segment   Treatment  Center  Number  Day      (BPM)    (ms)     (ms)     (ms)     (ms)    (NCS/CS)    Status Description  
_____________________________________________________________________________________________________________________________ _____________  
 
Double-blind      Placebo      02   [ZIP_CODE]  Screening         xxx    xxx      xxx      xxx      xxx     Normal        
        Day -2            xxx    xxx      xxx      xxx      xxx     Abnormal(NCS) N R  xxxxxxx      
        Day 1/Pre -dose    xxx    xxx      xxx      xxx      xxx     Normal      
        Day 2/Pre -dose    xxx    xxx      xxx      xxx      xxx     Normal       
        Day 29      xxx    xxx      xxx      xxx      xxx     Normal      
               ... 
   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  01    003    Screening        xxx    xxx      xxx      xxx      xxx     Normal        
           Day 0         xxx    xxx      xxx      xxx      xxx     Normal      
           Day 1/Pre -dose   xxx    xxx      xxx      xxx      xxx     Normal      
           Day 1/ 2 hr      xxx    xxx      xxx      xxx      xxx     Normal      
           Day 2/Pre -dose   xxx    xxx      xxx      xxx      xxx     Normal      
           Day 29     xxx    xxx      xxx      xxx      xxx     Normal      
 
                ... 
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
_____________________________________________________________________________________________________________________________ ______________  
 
Note: 
CS  = Clinically Significant  
NCS = Not Clinically Significant  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
                                                                         
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 91 of 100  
Listing 16.2. 8.6 Self Monitored Blood Glucose ( SMBG)  
 
__________________________________________________________________________________________________________ ___________________  
                          
Study      Subject        Visit            Results 
Segment  Treatment  Center  Number    Day    Date Time      (mg/dL)    
__________________________________________________________________________________________________________________ ___________  
 
Double-blind      Placebo    02  [ZIP_CODE]       DAY-14  ddmmmyyyy   HHMM     xxx 
        DAY-13  ddmmmyyyy    HHMM     xxx 
        DAY-12  ddmmmyyyy   HHMM     xxx 
        DAY-11  ddmmmyyyy   HHMM     xxx 
        DAY-10  ddmmmyyyy   HHMM     xxx 
        DAY-9  ddmmmyyyy   HHMM     xxx 
        DAY-8  ddmmmyyyy   HHMM     xxx 
        DAY-7  ddmmmyyyy   HHMM     xxx 
        DAY-6  ddmmmyyyy   HHMM     xxx 
        DAY-5  ddmmmyyyy   HHMM     xxx 
        DAY-4  ddmmmyyyy   HHMM     xxx 
        DAY-3  ddmmmyyyy   HHMM     xxx 
        DAY-2  ddmmmyyyy   HHMM     xxx 
        DAY-1  ddmmmyyyy   HHMM     xxx 
        DAY 0  ddmmmyyyy   HHMM     xxx 
        DAY 1  ddmmmyyyy   HHMM     xxx 
        DAY 2  ddmmmyyyy   UNK     xxx 
        DAY 3  ddmmmyyyy   UNK     xxx 
     
                                    ... 
                                  Day 43   ddmmmyyyy   HHMM     xxx 
               ... 
   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
___________________________________________________________________________________________________________ __________________  
 
Note: SMBG are measured daily after washout starts till the last termination visit.  
Note: table will continue for other Days.  
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)  
                                                                        
 
 
Theracos, Inc. Protocol No. THR -1442-C-[ADDRESS_617411]    Visit      from Body  Examination    
Segment  Treatment    Center   Number     Day      Previous System   Finding     
_____________________________________________________________________________________________________________________________  
 
Double-blind      Placebo       02  [ZIP_CODE]    Screening    Skin  Sunburn left hand (peeling skin)  
          Head   Normal   
          Eyes   Normal 
             Ears   Normal 
          Nose   Normal 
          Throat   Normal       
          Neck   Normal 
          Thyroid   Normal  
          Lungs   Normal 
          Heart   Normal 
          Abdomen   Normal  
          Lymph Nodes   Normal 
          Extremities   Normal 
 
         Day -2  Yes Skin   Normal 
 
    ... 
                                                    
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
________________________________________________________________________________________________________________ _____________  
 
Note: tab le will continue for Days 1,8,15,22, 29,35 and 43 for double -blind segment . 
      table will continue for screening, Days  0,1,3,8,15,22, 29 and 43 for dose escalation segment . 
 
 
(Source: path \program name  [CONTACT_1782]/time of run: ddmmmyyyy:hh:mm)     
    
                                                     
 
Theracos, Inc. Protocol No. THR-1442 -C-402 
Cetero Research Protocol No. CTJK09001  
______________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 93 of 100  
 
 
 
 
 
 
 
 
Figures  
 
 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 94 of 100  
 
Figure 14.2.1 Fasting Plasma Glucose (mean± SE)  - Double -blind Segment  
 
 
 
 
 
 
 
 
Time (Day) -2 1 2  8  15  22  29  35  43Fasting Plasma Glucose (mg/dL)
02004006008001000
Placebo
EGT0001442     5 mg
EGT0001442     10 mg
EGT0001442     20 mg
EGT0001442     50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 95 of 100  
 
Figure 14.2. 2 Fasting Plasma Glucose in Change from Baseline (mean± SE)  - Double -blind Segment  
 
 
 
 
Note:  Baseline is defined as the mean of FPG values on day -2 and day 1. 
  
Time (Day) 2  8  15  22  29  35  43Change in Fasting Plasma Glucose (mg/dL)
-600-400-2000200Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 96 of 100  
Similar Figures:  
 
 
Figure 14.2. 3 Body Weight  (mean± SE)  - Double -blind Segment  
 
 
Figure 14.2. 4 Body Weight  in Change from Baseline (mean± SE)  - Double -blind Segment  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 97 of 100  
Figure 14.2. 5 HbA1c ( mean± SE)  - Double -blind Segment   
 
 
         Predose  (Day 1)                                       Postdose  (Day 2 9) 
 
  
HbA1c (%)
02468101214 Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 98 of 100  
Figure 14.2. 6 24h UGE (mean± SE)  - Double -blind Segment  
 
 
 
 
         Predose  (Day 0 – Day 1)                                       Postdose  (Day 2 8 – Day 29)  
                     
  
UGE (g/day)
0102030405060708090100
Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 99 of 100  
Figure 14.2. 7 Mean Plasma Concentration for EGT0001442 (ng/mL)  - Dose Escalation  Segm ent  
 
 
        
 
 
 
 
 
 
Mean Graph 
Treatment: EGT0001442  5 mg
EGT0001442  10 mg
EGT0001442  20 mg
EGT0001442  50 mgConcentration (ng/mL)
0100200300400500600700800
Time (Hours)04812162024283236404448
Semi-Log Plot  
Treatment: EGT0001442  5 mg
EGT0001442  10 mg
EGT0001442  20 mg
EGT0001442  50 mgConcentration (ng/mL)
110100100010000
Time (Hours)04812162024283236404448
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 100 of 100  
 
Similar Figures:  
 
Figure 14.2. 8 Individual Plasma Concentration for EGT0001442 (ng/mL)  - Dose Escalation  Segm ent 
 